NeoCura PV
TM
For virus prophylaxis, NeoCura develops prophylactic mRNA vaccines for different viruses. For selected viral antigen targets, NeoCura self-designed mRNA could express related antigens in vitro and in vivo with high efficiency, activating antigen specific humoral and cellular immune response, producing antibodies and memory cells, to achieve a safe and effective virus prophylactic goal.
MRNA vaccine induced immune response
Product Highlights
Self adjuvant effects
Non-cell cultured vaccine products, safer
Low toxicity and no integrating risk
Fast vaccine design
Technical Superiority
Self-developed sequence optimization plaform£»
Relatively simple and fast vaccine design£»
Simple and standardized manufacture.
Clinical Value
For sudden infection pandemic or virus infections with no vaccines currently available, mRNA vaccine could be designed with high speed and efficiency.
mRNA vaccine is with relatively low toxicity, safe and reliable.
